Alan Forman
Direktor/Vorstandsmitglied bei JBG SMITH PROPERTIES
Vermögen: 75 450 $ am 30.04.2024
Aktive Positionen von Alan Forman
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
JBG SMITH PROPERTIES | Direktor/Vorstandsmitglied | 01.01.2017 | - |
Independent Dir/Board Member | 01.01.2017 | - | |
National Association of Corporate Directors (Virginia)
National Association of Corporate Directors (Virginia) Miscellaneous Commercial ServicesCommercial Services National Association of Corporate Directors provides online and print information services to directors of public companies. It offers in-boardroom education, evaluation, governance reviews, board composition and succession planning, board recruitment, ongoing advisory, insights, and analytics services. The company was founded in 1977 and is headquartered in Arlington, VA. | Corporate Officer/Principal | - | - |
JBG SMITH Properties LP
JBG SMITH Properties LP Real Estate DevelopmentFinance Part of JBG SMITH Properties, JBG SMITH Properties LP is a company based in Bethesda, MD. JBG SMITH Properties LP was founded in 1957. The CEO is W. Matthew Kelly. | Direktor/Vorstandsmitglied | - | - |
Institutionelle Verkäufe | - | - | |
Yale Investments Office | Chief Investment Officer | 01.10.1997 | - |
Lirum Therapeutics, Inc.
Lirum Therapeutics, Inc. BiotechnologyHealth Technology Lirum Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the treatment of deliberating diseases. The firm is also involved in the acquisition, development, and commercialization of drug candidates. Its products include LX-101, a targeted therapy directed to the insulin-like growth factor 1 (IGF-1R). The company was founded in November 2021 and is headquartered in New York, NY. | Direktor/Vorstandsmitglied | 01.05.2023 | - |
Karriereverlauf von Alan Forman
Ehemalige bekannte Positionen von Alan Forman
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Yale University Endowment
Yale University Endowment Investment Trusts/Mutual FundsMiscellaneous Since 1975, the Yale Corporation Investment Committee has been responsible for oversight of the Yale University Endowment. They are located in New Haven, Connecticut | Chief Investment Officer | 01.10.1997 | - |
Portfolio Manager-Aktien | 01.10.1990 | 01.03.2022 | |
STEMLINE THERAPEUTICS, INC. | Direktor/Vorstandsmitglied | 27.04.2015 | - |
Kimpton Group Holding LLC
Kimpton Group Holding LLC Hotels/Resorts/Cruise linesConsumer Services Kimpton Group Holding LLC operates hotels and restaurants. It is the parent company of Kimpton Hotels & Restaurants which is a collection of boutique hotels coupled with chef-driven restaurants. The company was founded in 1981 and is headquartered in San Francisco, CA | Direktor/Vorstandsmitglied | - | - |
ACADIA REALTY TRUST | Direktor/Vorstandsmitglied | 01.08.2002 | - |
Ausbildung von Alan Forman
Dartmouth College | Undergraduate Degree |
The Leonard N Stern School of Business | Masters Business Admin |
Statistik
International
Vereinigte Staaten | 12 |
Operativ
Director/Board Member | 6 |
Chief Investment Officer | 2 |
Corporate Officer/Principal | 1 |
Sektoral
Finance | 4 |
Consumer Services | 4 |
Health Technology | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 2 |
---|---|
ACADIA REALTY TRUST | Finance |
JBG SMITH PROPERTIES | Finance |
Private Unternehmen | 7 |
---|---|
Kimpton Group Holding LLC
Kimpton Group Holding LLC Hotels/Resorts/Cruise linesConsumer Services Kimpton Group Holding LLC operates hotels and restaurants. It is the parent company of Kimpton Hotels & Restaurants which is a collection of boutique hotels coupled with chef-driven restaurants. The company was founded in 1981 and is headquartered in San Francisco, CA | Consumer Services |
National Association of Corporate Directors (Virginia)
National Association of Corporate Directors (Virginia) Miscellaneous Commercial ServicesCommercial Services National Association of Corporate Directors provides online and print information services to directors of public companies. It offers in-boardroom education, evaluation, governance reviews, board composition and succession planning, board recruitment, ongoing advisory, insights, and analytics services. The company was founded in 1977 and is headquartered in Arlington, VA. | Commercial Services |
Yale University Endowment
Yale University Endowment Investment Trusts/Mutual FundsMiscellaneous Since 1975, the Yale Corporation Investment Committee has been responsible for oversight of the Yale University Endowment. They are located in New Haven, Connecticut | Miscellaneous |
Stemline Therapeutics, Inc.
Stemline Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, acquisition, development, and commercialization of novel therapeutics for oncology indications of unmet medical need. Its clinical stage product candidates include SL-401, SL-801, and SL-701. The SL-401, is a targeted therapy directed to the interleukin-3 receptor (CD123) present on a malignancies. The SL-801, is a novel oral small molecule reversible inhibitor of XPO1, that has demonstrated in vivo and in vitro preclinical activity in solid and hematologic malignancies. The SL-701, is an immunotherapy designed to activate the immune system to attack tumors. The company was founded by Ivan Bergstein on August 8, 2003 and is headquartered in New York, NY. | Health Technology |
JBG SMITH Properties LP
JBG SMITH Properties LP Real Estate DevelopmentFinance Part of JBG SMITH Properties, JBG SMITH Properties LP is a company based in Bethesda, MD. JBG SMITH Properties LP was founded in 1957. The CEO is W. Matthew Kelly. | Finance |
Yale Investments Office | |
Lirum Therapeutics, Inc.
Lirum Therapeutics, Inc. BiotechnologyHealth Technology Lirum Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the treatment of deliberating diseases. The firm is also involved in the acquisition, development, and commercialization of drug candidates. Its products include LX-101, a targeted therapy directed to the insulin-like growth factor 1 (IGF-1R). The company was founded in November 2021 and is headquartered in New York, NY. | Health Technology |
- Börse
- Insiders
- Alan Forman
- Erfahrung